Lilly study links Amyvid to changes in treatment

Eli Lilly and Co. (NYSE:LLY) presented data showing that knowledge of amyloid status measured by PET imaging agent Amyvid florbetapir led to changes in the diagnosis and management of patients being evaluated for cognitive decline.

Lilly spokesperson Nicole Hebert declined to comment on whether the company would reopen discussions with CMS on reimbursement for Amyvid based on the results. ...